Press | Navamedic

Navamedic ASA: Q4 2021 financial results

“The fourth quarter of 2021 was strong for Navamedic, resulting in a full year growth of 33%, compared to our targeted growth rate of 20%.

Treating the side-effects of the pandemic

Musculoskeletal pain is often a result of muscle tension and overexertion, psychological stress or working postures, often in combination with a sedentary lifestyle. Low back

Obesity patient support program launched in Norway

Navamedic, a Nordic pharma company, specialized in the field of obesity and Observia, French e-health company specialized in patient engagement and support solutions are proud

Navamedic ASA: Q1 2021 financial

“In the first quarter of 2021, we continued to deliver growth in our underlying portfolio. The rapid growth of specialty pharma product Mysimba and the

Navamedic ASA: Q4 2020 financial results

“The fourth quarter of 2020 displayed strong growth in our underlying portfolio and new products introduced during the second half of the year. Key growth

Navamedic ASA: Q3 2020 financial results

“In the third quarter of 2020, we delivered strong growth driven by both the addition of new products such as ThermaCare and positive performance in

MyControl Support – A brand new support program for patients with obesity

Today, Navamedic launches MyControl Support in Sweden – a completely new support program aimed for people with obesity. This is a first of its kind

MyControl – A new website to raise awareness about obesity among healthcare professionals and patients

This is the first step in a wave of communication as part of Navamedic’s effort to increase knowledge about obesity, and to address the fact